These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 7902431)
1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist. Wong PC; Duncia JV; Chiu AT; Olson RE; Rominger DH; Tam SW; Timmermans PB J Pharmacol Exp Ther; 1993 Nov; 267(2):641-7. PubMed ID: 7902431 [TBL] [Abstract][Full Text] [Related]
2. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632 [TBL] [Abstract][Full Text] [Related]
3. Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. Keiser JA; Ryan MJ; Panek RL; Hodges JC; Sircar I J Pharmacol Exp Ther; 1995 Mar; 272(3):963-9. PubMed ID: 7891350 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology of 2-amino-1,4-dihydro-4-(2-[4-[4-(2-methoxyphenyl)-1- piperazinyl]butylsulfinyl]phenyl)-6-methyl-5-nitro-3-pyridine carboxylic acid methyl ester (XB513), a novel calcium agonist with alpha-1 adrenergic receptor antagonistic. Wong PC; Aldrich PE; Chiu AT; Earl RA; Hart SD; Johnson AL; Ma P; McCall DE; Price WA; Smith RD J Pharmacol Exp Ther; 1993 Jun; 265(3):1088-95. PubMed ID: 8099616 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist. Olins GM; Corpus VM; Chen ST; McMahon EG; Palomo MA; McGraw DE; Smits GJ; Null CL; Brown MA; Bittner SE J Cardiovasc Pharmacol; 1993 Oct; 22(4):617-25. PubMed ID: 7505365 [TBL] [Abstract][Full Text] [Related]
6. Evidence for adrenergic and tachykinin activity in venom of the stonefish (Synanceja trachynis). Hopkins BJ; Hodgson WC; Sutherland SK Toxicon; 1996 May; 34(5):541-54. PubMed ID: 8783449 [TBL] [Abstract][Full Text] [Related]
7. Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor. Nouet S; Dodey P; Renaut P; Marie J; Pruneau D; Larguier R; Lombard C; Bonnafous JC Mol Pharmacol; 1994 Oct; 46(4):693-701. PubMed ID: 7969048 [TBL] [Abstract][Full Text] [Related]
8. Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753. Wong PC; Price WA; Chiu AT; Carini DJ; Duncia JV; Johnson AL; Wexler RR; Timmermans PB Hypertension; 1990 Jun; 15(6 Pt 2):823-34. PubMed ID: 2351436 [TBL] [Abstract][Full Text] [Related]
9. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. Levy BI; Benessiano J; Henrion D; Caputo L; Heymes C; Duriez M; Poitevin P; Samuel JL J Clin Invest; 1996 Jul; 98(2):418-25. PubMed ID: 8755652 [TBL] [Abstract][Full Text] [Related]
10. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. Chiu AT; McCall DE; Price WA; Wong PC; Carini DJ; Duncia JV; Wexler RR; Yoo SE; Johnson AL; Timmermans PB J Pharmacol Exp Ther; 1990 Feb; 252(2):711-8. PubMed ID: 2313596 [TBL] [Abstract][Full Text] [Related]
11. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist. Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160 [TBL] [Abstract][Full Text] [Related]
12. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971. Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613 [TBL] [Abstract][Full Text] [Related]
13. Vascular angiotensin II receptor and calcium signaling in toadfish. Qin ZL; Yan HQ; Nishimura H Gen Comp Endocrinol; 1999 Jul; 115(1):122-31. PubMed ID: 10375471 [TBL] [Abstract][Full Text] [Related]
14. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model]. Ponchon P; Elghozi JL Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874 [TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat. Uhlenius N; Vuolteenaho O; Tikkanen I J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129 [TBL] [Abstract][Full Text] [Related]
16. Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. Mochizuki S; Sato T; Furuta K; Hase K; Ohkura Y; Fukai C; Kosakai K; Wakabayashi S; Tomiyama A J Cardiovasc Pharmacol; 1995 Jan; 25(1):22-9. PubMed ID: 7723348 [TBL] [Abstract][Full Text] [Related]
18. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Sheu MM; Wu BN; Ho WC; Hong SJ; Chen SJ; Lin YT; Chen IJ Pharmacology; 1997 Apr; 54(4):211-24. PubMed ID: 9211567 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent. Asano M; Uchida W; Shibasaki K; Terai M; Inagaki O; Takenaka T; Matsumoto Y; Fujikura T J Pharmacol Exp Ther; 1990 Jul; 254(1):204-11. PubMed ID: 1973196 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. Wong YN; Wong PC J Pharm Pharmacol; 1996 May; 48(5):492-7. PubMed ID: 8799873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]